Yu et al. assessed the combined effect of ARQ 092, a pan-AKT inhibitor, and ARQ 087, a pan-FGFR inhibitor, in nude mice using the AN3CA endometrial adenocarcinoma cell line and patient-derived tumors bearing PIK3CA and FGFR mutations. This evidence concerns the gene AKT1 and endometrium adenocarcinoma.